United Kingdom· GB-APID-34646211000001100
Besponsa 1mg powder for concentrate for solution for infusion vials
A inotuzumab ozogamicin product containing inotuzumab ozogamicin, registered in United Kingdom by Pfizer Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Inotuzumab ozogamicin is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FB01 (inotuzumab ozogamicin), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Inotuzumab ozogamicin · ATC L01FB01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of inotuzumab ozogamicin costs, country by country.
Normalised to the WHO defined daily dose (0.1 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Inotuzumab ozogamicin · price per daily dose (0.1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1418.36
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Inotuzumab ozogamicin
- Manufacturer
- Pfizer Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FB01
- ATC class
- Inotuzumab ozogamicin
- Defined daily dose
- 0.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5013457012095
- gtin5415062370537
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
362 interactions on record for inotuzumab ozogamicin.
Graded by severity as the source publishes them — 96 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Inotuzumab ozogamicin · interactions on record
362 records
- 96 severe
- 263 moderate
- 3 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Inotuzumab ozogamicin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBesponsa 1 mgPfizer Europe MA
- CzechiaBESPONSAPfizer Europe MA EEIG, Bruxelles
- SpainBESPONSA 1 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer Europe Ma Eeig
- FinlandBesponsaPfizer Europe MA EEIG
- IrelandBESPONSA 1 mg powder for concentrate for solution for infusionPfizer Europe MA EEIG
- IcelandBesponsaPfizer Europe MA EEIG*
- NorwayBesponsaPfizer Europe MA EEIG (1)
- PolandBesponsaPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Besponsa
- Liechtenstein · Besponsa
- Norway · Besponsa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/70f129f7-6385-44cc-89c1-44b946045392 GET /v1/drugs/70f129f7-6385-44cc-89c1-44b946045392?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "34646211000001100",
"desc": "Besponsa 1mg powder for concentrate for solution for infusion vials (Pfizer Ltd)",
"form": "Powder for solution for infusion",
"vpid": "34665011000001106",
"source": "dmd",
"vtm_id": "776336004",
"strength": "1 mg",
"substance": "Inotuzumab ozogamicin",
"ingredient": "Inotuzumab ozogamicin",
"supplier_code": "2082201000001106"
}See everything about inotuzumab ozogamicin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.